-
Innovation Ranking
NewInnovation Ranking – Clinigen Group Plc
Clinigen Ltd (Clinigen) is a pharmaceutical and services company that provides access to clinical trials, medicines and unlicensed and commercial supplies. The company’s products include dexrazoxane, crisantaspase, amifostine, foscarnet sodium, acetylcysteine, cholecalciferol, folic acid, gabapentin, glycopyrronium bromide, iloprost, and others. It carries out clinical trial services, partnering, IDIS-managed access, clinical supply management, and others. Clinigen's clinical trial services comprise packaging and labeling, direct-to-site delivery, global storage and distribution, ancillary supply sourcing, and controlled drug services. The company serves biotechnology and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Interferon Gamma-1b in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Interferon Gamma-1b in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interferon Gamma-1b in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Interferon Gamma-1B in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Interferon Gamma-1B in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interferon Gamma-1B in Metastatic Breast Cancer Drug Details: Human...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Interferon Gamma-1b in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Interferon Gamma-1b in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Interferon Gamma-1b in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Siremadlin Succinate in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Siremadlin Succinate in Myelofibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Siremadlin Succinate in Myelofibrosis Drug Details: Siremadlin succinate (HDM-201) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LBL-007 in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LBL-007 in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LBL-007 in Hypopharyngeal Cancer Drug Details: LBL-007 is under development for...
-
Product Insights
Gastrointestinal Stromal Tumor (GIST) – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastrointestinal Stromal Tumor (GIST) - Drugs In Development, 2023’, provides an overview of the Gastrointestinal Stromal Tumor (GIST) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Mesenchymal Tumor Of The Gastrointestinal Tract – Drugs In Development, 2023
Global Markets Direct’s, ‘Mesenchymal Tumor Of The Gastrointestinal Tract - Drugs In Development, 2023’, provides an overview of the Mesenchymal Tumor Of The Gastrointestinal Tract pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mesenchymal Tumor Of The Gastrointestinal Tract, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Chondrosarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Chondrosarcoma - Drugs In Development, 2023’, provides an overview of the Chondrosarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chondrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Drugs In Development, 2023’, provides an overview of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...